Perimeter Medical Q2 Revenue Doubles to $500K, Driven by Procedure and Recurring Revenue Growth
PorAinvest
lunes, 11 de agosto de 2025, 4:33 pm ET1 min de lectura
PMTR--
The company expects its gross margin for Q2 2025 to be 69%, aligning with previous guidance. Additionally, Perimeter Medical Imaging AI projects H1 2025 revenue of $1.0 million, surpassing full-year 2024 revenue of $846,000 [2].
To support its growth, Perimeter Medical Imaging AI has announced a significant 30% reduction in operating costs starting Q3 2025. Key leadership appointments include Abbey Goodman as VP of Sales and Paolo DiPasquale as VP of Corporate Development. Additionally, the company has established an Industry Advisory Board (IAB) to be chaired by Diana Chan, with COO Tom Boon continuing to serve on the IAB [2].
References:
[1] https://seekingalpha.com/news/4483469-perimeter-medical-reports-preliminary-q2-revenue-of-500k-up-100-yoy
[2] https://www.stocktitan.net/news/PYNKF/perimeter-announces-preliminary-unaudited-revenues-for-the-2025-bnayh777unla.html
PRM--
Perimeter Medical Imaging AI reports preliminary Q2 2025 revenue of $500,000, a 100% YoY increase. Revenue growth is driven by a 35% increase in procedures and a 50% increase in recurring revenue compared to Q1 2025. The company's gross margin is expected to be in line with previous guidance.
Perimeter Medical Imaging AI (TSXV:PINK, OTCQX:PYNKF) has reported preliminary Q2 2025 revenue of approximately $500,000, representing a 100% year-over-year (YoY) increase. The company's revenue growth is primarily driven by a 35% increase in procedures and a 50% increase in recurring revenue compared to Q1 2025 [1].The company expects its gross margin for Q2 2025 to be 69%, aligning with previous guidance. Additionally, Perimeter Medical Imaging AI projects H1 2025 revenue of $1.0 million, surpassing full-year 2024 revenue of $846,000 [2].
To support its growth, Perimeter Medical Imaging AI has announced a significant 30% reduction in operating costs starting Q3 2025. Key leadership appointments include Abbey Goodman as VP of Sales and Paolo DiPasquale as VP of Corporate Development. Additionally, the company has established an Industry Advisory Board (IAB) to be chaired by Diana Chan, with COO Tom Boon continuing to serve on the IAB [2].
References:
[1] https://seekingalpha.com/news/4483469-perimeter-medical-reports-preliminary-q2-revenue-of-500k-up-100-yoy
[2] https://www.stocktitan.net/news/PYNKF/perimeter-announces-preliminary-unaudited-revenues-for-the-2025-bnayh777unla.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios